OUR TEAM
05 Jun 2024
Maria Bech spoke at the first ever BioStock Global Forum in Lund, Sweden
REYKJAVIK, ICELAND – 5 June 2024 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has posted a video of CEO Maria Bech speech at BioStock Global Forum from 29th of May.
Maria Bech gave a short presentation of EpiEndo and the company's clinical candidate EP395 at BioStock Global Forum on May 29th, 2024. Below you can watch her presentaiton.
Contact
EpiEndo Pharmaceuticals:
Maria Bech, CEO
E-mail: maria.bech@epiendo.com
Tel: +354 454 0090
About EpiEndo Pharmaceuticals (www.epiendo.com)
EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the role of epithelial function in various inflammatory disorders. Epithelial cells are a key part of the barrier that makes up human lung tissue and other organs such as the gut and skin.
EpiEndo’s new class of orally available macrolide, with reduced antimicrobial resistance (AMR) potential, known as ‘Barriolides™’, show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo’s lead asset, EP395, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD).
EP395 aims to be the first on-market oral, barrier-enhancing and anti-inflammatory drug, which has the potential to be a unique and impactful treatment option for COPD patients. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.
